1h 7 min
Prostate Cancer | Exploring the Current and Future Role of PARP Inhibition in the Management of Prostate Cancer Research To Practice | Oncology Videos
-
- Ciencia
A roundtable discussion about prostate cancer featuring perspectives from Drs Neeraj Agarwal, Emmanuel S Antonarakis and A Oliver Sartor.
Integrating PARP inhibitors into the treatment algorithm for patients with prostate cancer (PC) (00:00) Role of PARP enzymes in DNA damage repair and mechanism of action of PARP inhibitors (04:25) Genetic testing for patients with PC (06:31) Correlation between Gleason score and incidence of DNA repair gene mutations in patients with localized PC (11:24) Role of platinum-based chemotherapy for patients with PC and DNA repair gene mutations (15:34) Sequencing PARP inhibitors and chemotherapy for patients with PC and DNA repair gene mutations(19:40) Case (Dr Antonarakis): A man in his mid-40s with castration-resistant PC (CRPC), a BRCA2 mutation and lung metastases attains an excellent response to olaparib on a clinical trial (23:28) Tolerability and side effects of PARP inhibitors (27:59) Case (Dr Antonarakis): A man in his late 40s with metastatic hormone-sensitive PC and biallelic BRCA2 mutations receives PARP inhibitor monotherapy on a clinical trial (35:21) Perspective on the potential use of PARP inhibitor monotherapy in the first-line setting for patients with hormone-sensitive PC and DNA repair gene mutations (39:49) Tolerability of PARP-inhibitor monotherapy in the first-line setting (45:11) Case (Dr Sartor): A man in his late 60s with metastatic CRPC (mCRPC) and a germline BRCA2 mutation receives olaparib (49:08) Dosing and PARP trapping activity of PARP inhibitors (51:39) Case (Dr Agarwal): A man in his late 60s with progressive mCRPC is enrolled on the TALAPRO-2 trial of enzalutamide with or without talazoparib (55:07) Efficacy and tolerability of PARP inhibitors alone or in combination with endocrine therapy (59:32) Response to PARP inhibitors in patients with PALB2, FANCA and RAD51 mutations; clinical care of patients with PC during the COVID-19 pandemic (1:03:48) CME information and select publications
A roundtable discussion about prostate cancer featuring perspectives from Drs Neeraj Agarwal, Emmanuel S Antonarakis and A Oliver Sartor.
Integrating PARP inhibitors into the treatment algorithm for patients with prostate cancer (PC) (00:00) Role of PARP enzymes in DNA damage repair and mechanism of action of PARP inhibitors (04:25) Genetic testing for patients with PC (06:31) Correlation between Gleason score and incidence of DNA repair gene mutations in patients with localized PC (11:24) Role of platinum-based chemotherapy for patients with PC and DNA repair gene mutations (15:34) Sequencing PARP inhibitors and chemotherapy for patients with PC and DNA repair gene mutations(19:40) Case (Dr Antonarakis): A man in his mid-40s with castration-resistant PC (CRPC), a BRCA2 mutation and lung metastases attains an excellent response to olaparib on a clinical trial (23:28) Tolerability and side effects of PARP inhibitors (27:59) Case (Dr Antonarakis): A man in his late 40s with metastatic hormone-sensitive PC and biallelic BRCA2 mutations receives PARP inhibitor monotherapy on a clinical trial (35:21) Perspective on the potential use of PARP inhibitor monotherapy in the first-line setting for patients with hormone-sensitive PC and DNA repair gene mutations (39:49) Tolerability of PARP-inhibitor monotherapy in the first-line setting (45:11) Case (Dr Sartor): A man in his late 60s with metastatic CRPC (mCRPC) and a germline BRCA2 mutation receives olaparib (49:08) Dosing and PARP trapping activity of PARP inhibitors (51:39) Case (Dr Agarwal): A man in his late 60s with progressive mCRPC is enrolled on the TALAPRO-2 trial of enzalutamide with or without talazoparib (55:07) Efficacy and tolerability of PARP inhibitors alone or in combination with endocrine therapy (59:32) Response to PARP inhibitors in patients with PALB2, FANCA and RAD51 mutations; clinical care of patients with PC during the COVID-19 pandemic (1:03:48) CME information and select publications
1h 7 min